BURLINGTON, Mass., Dec. 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to analysis of U.S. longitudinal patient-level claims data, the first-line use of monoamine oxidase (MAO)-B inhibitors among newly diagnosed Parkinson's disease (PD) patients has declined slightly over the four quarters ending June 2013, capturing 11 percent patient share in Q2 2013. Meanwhile, the analysis shows the uptake of dopamine agonists slightly grew as first-line treatments during this time, reaching 14 percent patient share in Q2 2013. These shifts may suggest a growing preference for dopamine agonists over MAO-B inhibitors in treatment-naive patients, most likely in the early stages of PD–a finding that could be attributed to U.S. regulators' early 2012 denial of Teva's application to add a delay in clinical disease progression claim to the label of Azilect, the company's market-leading MAO-B inhibitor.

The report Treatment Algorithms in Parkinson's Disease also finds that UCB's Neupro, a novel, once-daily transdermal dopamine agonist that was relaunched in the United States for the treatment of PD in July 2012, garnered a total patient share of 3 percent among recently treated patients in Q2 2013, more than doubling over the previous year. Though its use is still modest overall, the patient share of Neupro in the last quarter under study exceeded that of Boehringer Ingelheim's long-acting oral dopamine agonist brand Mirapex ER, which has been available since 2010. The majority of patients treated with Neupro in Q2 2013 either switched to the drug from another agent or added Neupro to their current drug regimen.

"The relative stability of the treatment algorithm in PD and the pervasive use of generics make the success of branded agents in this market, namely the continued reliance on Azilect and uptake of Neupro, particularly striking," said Decision Resources Senior Business Insights Analyst Nadja Rozovsky, Ph.D. "Perhaps not surprisingly, our analysis of patients' pathway to therapy suggests that Neupro is making inroads mostly in later lines of therapy, driven by its unique clinical profile, as both a new chemical entity and a transdermal patch formulation–features that translate into a significant market advantage in appropriate patients."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE Decision Resources

Value-Based Pricing is a Double-Edged Sword for Drug Manufacturers

View Now